Why Hims & Hers Health Stock Sank This Week
Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...
BUZZ Investing: Markets Navigate Policy Shifts
The BUZZ NextGen AI US Sentiment Leaders Index returned 2.66% during the month of January, compared to a return of 2.78% for the S&P 500 Index during the same period.
Investor's Business Daily on MSN4h
Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up
Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...
Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate
When asked whether we’ll ever find out who was behind the selloff, the CNBC TV show host stated: “Well no, and you never will ...
Modern Healthcare12h
Digital health companies see opportunity in regulatory upheaval
Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $40.00
Hims & Hers Health (NYSE:HIMS – Free Report) had its price objective hoisted by Leerink Partners from $24.00 to $40.00 in a report published on Tuesday,Benzinga reports. They currently have a market ...
Promising Medical Stocks To Add to Your Watchlist – February 26th
Eli Lilly and Company, Hims & Hers Health, UnitedHealth Group, Walmart, Tempus AI, Johnson & Johnson, and Merck & Co., Inc. are the seven Medical stocks to watch today, according to MarketBeat’s stock ...
Modern Healthcare1d
GLP-1 compounding pharmacies sue FDA over shortage decision
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
Hims & Hers: Brace For Impact As It Faces A Possible 18% Revenue Hit
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
Eli Lilly cuts price of weight-loss drug Zepbound as competition heats up
Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...
The GLP-1 Revolution — How Private Equity Investors Are Capitalizing
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
Hims & Hers Health, Inc.: Jim Cramer Warns ‘The Gravy Train Might Be Over’ After FDA’s Ozempic Update
We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...